UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 368

Sortiert nach

3-Year CheckMate743 outcomes: ringing in immunotherapy for the treatment of malignant pleural mesothelioma

Annals of oncology, 2022-05, Vol.33 (5), p.457-459

2022

Link zum Volltext

Verfügbarkeit prüfen

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)

Annals of oncology, 2017-10, Vol.28 (10), p.2451-2457

2017

Link zum Volltext

Verfügbarkeit prüfen

Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients

Clinical & translational oncology, 2020-08, Vol.22 (8), p.1390-1398

2020

Link zum Volltext

Verfügbarkeit prüfen

STELLAR: Final updated results of a phase II trial of TTFields with chemotherapy for unresectable malignant pleural mesothelioma

Annals of oncology, 2019-04, Vol.30, p.ii72-ii72

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial

ESMO open, 2023-06, Vol.8 (3), p.101576-101576, Article 101576

2023

Link zum Volltext

Verfügbarkeit prüfen

STELLAR: Final results of a phase II trial of TTFields with chemotherapy for first-line treatment of pleural mesothelioma

Annals of oncology, 2018-10, Vol.29, p.viii641-viii641

2018

Link zum Volltext

Verfügbarkeit prüfen

Long duration of immunotherapy in a STK11 mutated/KRAS wild-type non-small cell lung cancer patient

Pulmonology, 2020-01, Vol.26 (1), p.49-50

2020

Link zum Volltext

Verfügbarkeit prüfen

Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer

Clinical & translational oncology, 2012-11, Vol.14 (11), p.864-869

2012

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant chemotherapy in non-small cell lung cancer (NSCLC)

Annals of oncology, 2007-07, Vol.18 (suppl-9), p.ix143-ix146

2007

Link zum Volltext

Verfügbarkeit prüfen

Exploratory analysis of activation of PTEN–PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM)

Lung cancer (Amsterdam, Netherlands), 2012-07, Vol.77 (1), p.192-198

2012

Link zum Volltext

Verfügbarkeit prüfen

SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)

Clinical & translational oncology, 2021-05, Vol.23 (5), p.980-987

2021

Link zum Volltext

Verfügbarkeit prüfen

116P RETROSPECTIVE ANALYSIS OF PATIENTS WITH THYMIC MALIGNANCIES TREATED AT THE VALL D'HEBRON UNIVERSITY HOSPITAL

Lung cancer (Amsterdam, Netherlands), 2013-05, Vol.80, p.S50-S50

2013

Link zum Volltext

Verfügbarkeit prüfen

1443 POSTER High Blood Neutrophil-to-lymphocyte Ratio as an Indicator of Poor Prognosis in Advanced Non Small Cell Lung Cancer

European journal of cancer (1990), 2011, Vol.47, p.S182-S182

2011

Link zum Volltext

Verfügbarkeit prüfen

Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: current status and future approaches

Lung cancer (Amsterdam, Netherlands), 2017-04, Vol.106, p.70-75

2017

Link zum Volltext

Verfügbarkeit prüfen

Analysis of expression of PTEN/PI3 K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)

Lung cancer (Amsterdam, Netherlands), 2016-06

2016

Link zum Volltext

Verfügbarkeit prüfen

Multiple primary cancers (MPC) in a series of lung cancer (LC) patient: Incidence and outcome

Annals of oncology, 2018-10, Vol.29, p.viii641-viii641

2018

Link zum Volltext

Verfügbarkeit prüfen

UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma – A phase II randomised trial

European journal of cancer (1990), 2024-05, Vol.202, p.113973-113973, Article 113973

2024

Link zum Volltext

Verfügbarkeit prüfen

The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma

Journal of thoracic oncology, 2016-12, Vol.11 (12), p.2089-2099

2016

Link zum Volltext

Verfügbarkeit prüfen

P24.07 Nivolumab and Ipilimumab +/- UV1 Vaccination as 2nd Line Treatment in Patients with Malignant Mesothelioma (the NIPU-Study)

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S380-S380

2021

Link zum Volltext

Verfügbarkeit prüfen

1910P Outcomes of systemic therapy after first line therapy in patients (p) with malignant pleural mesothelioma (MPM)

Annals of oncology, 2020-09, Vol.31, p.S1082-S1082

2020

Link zum Volltext

Verfügbarkeit prüfen

1798P Carboplatin-paclitaxel (CP) chemotheraphy as salvage treatment for small cell lung cancer (SCLC): A real-world evidence analysis

Annals of oncology, 2020-09, Vol.31, p.S1041-S1041

2020

Link zum Volltext

Verfügbarkeit prüfen

LBA66 Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial

Annals of oncology, 2021-09, Vol.32, p.S1342-S1342

2021

Link zum Volltext

Verfügbarkeit prüfen

1733P Analysis of chemotherapy (Ct) efficacy according to histology in malignant pleural mesothelioma (MPM) patients (p)

Annals of oncology, 2021-09, Vol.32, p.S1199-S1200

2021

Link zum Volltext

Verfügbarkeit prüfen

EP07.01-023 Family History of Cancer in a Series of Malignant Pleural Mesothelioma (MPM) Patients (P)

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S323-S324

2022

Link zum Volltext

Verfügbarkeit prüfen

EP07.01-022 Analysis of Second Surgery for Recurrence in Malignant Pleural Mesothelioma (MPM) Patients (P)

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S323

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 368

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(341)
Mit Volltextzugriff
(350)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(158)
Life Sciences & Biomedicine
(102)
Humans
(85)
Male
(51)
Female
(47)
Oncology
(45)
Physical Sciences
(43)
Middle Aged
(36)
Adult
(30)
Aged
(29)
Technology
(25)
Astronomy & Astrophysics
(24)
Immunotherapy
(21)
Lung Neoplasms - Pathology
(20)
Lung Neoplasms - Drug Therapy
(19)
Biological And Medical Sciences
(17)
Computer Science
(17)
Tumors
(17)
Hematology, Oncology And Palliative Medicine
(16)
Mesothelioma
(16)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

3-Year CheckMate743 outcomes: ringing in immunotherapy for the treatment of malignant pleural mesothelioma

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)

Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients

STELLAR: Final updated results of a phase II trial of TTFields with chemotherapy for unresectable malignant pleural mesothelioma

Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial

STELLAR: Final results of a phase II trial of TTFields with chemotherapy for first-line treatment of pleural mesothelioma

Long duration of immunotherapy in a STK11 mutated/KRAS wild-type non-small cell lung cancer patient

Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer

Adjuvant chemotherapy in non-small cell lung cancer (NSCLC)

Exploratory analysis of activation of PTEN–PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM)

SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)

116P RETROSPECTIVE ANALYSIS OF PATIENTS WITH THYMIC MALIGNANCIES TREATED AT THE VALL D'HEBRON UNIVERSITY HOSPITAL

1443 POSTER High Blood Neutrophil-to-lymphocyte Ratio as an Indicator of Poor Prognosis in Advanced Non Small Cell Lung Cancer

Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: current status and future approaches

Analysis of expression of PTEN/PI3 K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)

Multiple primary cancers (MPC) in a series of lung cancer (LC) patient: Incidence and outcome

UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma – A phase II randomised trial

The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma

P24.07 Nivolumab and Ipilimumab +/- UV1 Vaccination as 2nd Line Treatment in Patients with Malignant Mesothelioma (the NIPU-Study)

1910P Outcomes of systemic therapy after first line therapy in patients (p) with malignant pleural mesothelioma (MPM)

1798P Carboplatin-paclitaxel (CP) chemotheraphy as salvage treatment for small cell lung cancer (SCLC): A real-world evidence analysis

LBA66 Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial

1733P Analysis of chemotherapy (Ct) efficacy according to histology in malignant pleural mesothelioma (MPM) patients (p)

EP07.01-023 Family History of Cancer in a Series of Malignant Pleural Mesothelioma (MPM) Patients (P)

EP07.01-022 Analysis of Second Surgery for Recurrence in Malignant Pleural Mesothelioma (MPM) Patients (P)

Suchergebnisse filtern